Drugs / Neuro-Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04205019 | Nov 2020 → Jun 2021 | spinal cord injury | Neuroplast | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03935724 | Jan 2022 → Feb 2024 | paraplegia, spinal cord injury | Neuroplast | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neuro-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03935724 ↗ |
| Modality | Cell therapy | “Neuro-Cells is an autologous fresh stem cells containing product” NCT03935724 ↗ |
| Route | Other | “will undergo three LPs, performed to administer Neuro-Cells or placebo” NCT03935724 ↗ |